HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Favorable evolution of lung interstitial disease in a patient with chronic myelomonocytic leukemia treated with azacitidine.

AuthorsMarc Hilmi, Cécile Bally, Robert Burns, Gwenael Lorillon, Anne Bergeron, Pierre Fenaux, Lionel Ades
JournalAnnals of hematology (Ann Hematol) Vol. 97 Issue 3 Pg. 541-542 (Mar 2018) ISSN: 1432-0584 [Electronic] Germany
PMID29170809 (Publication Type: Case Reports, Letter)
Chemical References
  • Antimetabolites, Antineoplastic
  • Azacitidine
  • Prednisone
  • Hydroxyurea
Topics
  • Antimetabolites, Antineoplastic (therapeutic use)
  • Azacitidine (therapeutic use)
  • Combined Modality Therapy
  • Drug Resistance
  • Humans
  • Hydroxyurea (therapeutic use)
  • Leukemia, Myelomonocytic, Chronic (complications, drug therapy)
  • Lung Diseases, Interstitial (diagnostic imaging, drug therapy, etiology, therapy)
  • Male
  • Middle Aged
  • Oxygen Inhalation Therapy
  • Prednisone (therapeutic use)
  • Tomography, X-Ray Computed

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: